Program
BL-M24D1
Its studies are mostly in Multiple Myeloma · Digestive System Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung, led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 44 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | Nov 2027phase 1 · NCT07232524 |
Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2025First studies: 3 phase 1 studiesFirst studyNCT07232524, NCT07232420, NCT07255898
- Dec 1, 2025Phase 1 study in Digestive System NeoplasmsNCT07279428 · 33 planned · China
Ahead
- Nov 2027Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT07232524
- Dec 2027Primary completion: phase 1 study in Digestive System NeoplasmsNCT07279428
- Dec 2027Primary completion: phase 1 study in Multiple MyelomaNCT07255898
- Dec 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07232420
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07279428Digestive System Neoplasms · China | 1 | Recruiting | Dec 2027 | 33 |
| NCT07255898Multiple Myeloma · China | 1 | Recruiting | Dec 2027 | 33 |
| NCT07232524Squamous Cell Carcinoma of Head and Neck · China | 1 | Recruiting | Nov 2027 | 16 |
| NCT07232420Carcinoma, Non-Small-Cell Lung · China | 1 | Recruiting | Dec 2027 | 33 |
How it is read
Names in the registry
- “BL-M24D1”, 4 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 1 study
- Digestive System Neoplasms, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.